Literature DB >> 12616449

Epidemiology and prevention of hepatitis B.

Miriam J Alter1.   

Abstract

The primary goal of hepatitis B prevention programs is reduction of chronic hepatitis B virus (HBV) infection and HBV-related chronic liver disease. Although donor screening, risk-reduction counseling and services, and effective infection control practices can reduce or eliminate the potential risk for HBV transmission, immunization is by far the single most effective prevention measure. Worldwide, the integration of hepatitis B vaccine into existing childhood vaccination schedules has the greatest likelihood of long-term success. However, by 2000, only 116 of 215 countries had such a policy, representing 31% of the global birth cohort. In addition, efforts must be strengthened to vaccinate older adolescents and adults with high-risk behaviors or occupations in countries where most HBV transmission and the morbidity associated with acute hepatitis B occur among persons in these age groups. Although continued immunization of successive birth cohorts should achieve the eventual elimination of HBV transmission, this will not occur for decades without successful vaccination of adults at increased risk for infection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12616449     DOI: 10.1055/s-2003-37583

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  45 in total

1.  Ethnic differences in prevalence and barriers of HBV screening and vaccination among Asian Americans.

Authors:  Carol Strong; Sunmin Lee; Miho Tanaka; Hee-Soon Juon
Journal:  J Community Health       Date:  2012-10

2.  Recent epidemiological and clinical features of acute hepatitis B in a single center of China.

Authors:  Xiaohong Chen; Chengtao Fu; Jia Liu; Lei Shan; Chenglin Liu
Journal:  Int J Clin Exp Med       Date:  2015-09-15

Review 3.  Contingency Management Interventions for HIV, Tuberculosis, and Hepatitis Control Among Individuals With Substance Use Disorders: A Systematized Review.

Authors:  Evan S Herrmann; Alexis K Matusiewicz; Maxine L Stitzer; Stephen T Higgins; Stacey C Sigmon; Sarah H Heil
Journal:  J Subst Abuse Treat       Date:  2016-06-24

4.  New horizons for studying human hepatotropic infections.

Authors:  Ype P de Jong; Charles M Rice; Alexander Ploss
Journal:  J Clin Invest       Date:  2010-02-22       Impact factor: 14.808

5.  Is hepatitis C virus positivity a contributing factor to occult hepatitis B virus infection in hemodialysis patients?

Authors:  Mehmet Kanbay; Gurden Gur; Ali Akcay; Haldun Selcuk; Ugur Yilmaz; Hande Arslan; Sedat Boyacioglu; Fatma Nurhan Ozdemir
Journal:  Dig Dis Sci       Date:  2006-09-15       Impact factor: 3.199

Review 6.  Immunotherapeutic relief from persistent infections and amyloid disorders.

Authors:  Dorian B McGavern
Journal:  Neurology       Date:  2006-01-24       Impact factor: 9.910

7.  Prevalence of Blood Brotherhood among High School Students in Erzurum and the Effect of Peer-led Education on this Practice.

Authors:  Memet Isik; Turan Set; Abdul Sattar Khan; Ummu Zeynep Avsar; Zeliha Cansever; Hamit Acemoglu
Journal:  Eurasian J Med       Date:  2013-06

Review 8.  Accuracy of Rapid Point-of-Care Diagnostic Tests for Hepatitis B Surface Antigen-A Systematic Review and Meta-analysis.

Authors:  Mehnaaz S Khuroo; Naira S Khuroo; Mohammad S Khuroo
Journal:  J Clin Exp Hepatol       Date:  2014-08-28

9.  Lay beliefs about hepatitis among North American Chinese: implications for hepatitis prevention.

Authors:  Hueifang Chen; Shin-Ping Tu; Chong Z Teh; Mei-Po Yip; John H Choe; T Gregory Hislop; Victoria M Taylor; Beti Thompson
Journal:  J Community Health       Date:  2006-04

10.  Risk factors for chronic liver disease in Blacks, Mexican Americans, and Whites in the United States: results from NHANES IV, 1999-2004.

Authors:  Yvonne N Flores; Hal F Yee; Mei Leng; José J Escarce; Roshan Bastani; Jorge Salmerón; Leo S Morales
Journal:  Am J Gastroenterol       Date:  2008-07-30       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.